Breaking News Instant updates and real-time market news.

NVAX

Novavax

$6.26

0.21 (3.47%)

, AKRX

Akorn

$4.41

0.215 (5.13%)

08:45
05/22/19
05/22
08:45
05/22/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Novavax (NVAX) 5.74% +0.11, Akorn (AKRX) 0.59% +0.09, ProShares Ultra VIX Short Term Futures (UVXY) 4.24% +0.05, Avon Products (AVP) 0.45% +0.03, Maxar Technologies (MAXR) 2.11% +0.03, Jumia Technologies (JMIA) 14.88% +0.02, BP (BP) 0.29% +0.02, ProShares UltraPro Short Dow 30 (SDOW) 2.74% +0.01, Powershares Loan ETF (BKLN) 0.29% +0.01, and Bloom Energy (BE) 2.14% +0.01.

NVAX

Novavax

$6.26

0.21 (3.47%)

AKRX

Akorn

$4.41

0.215 (5.13%)

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$34.65

-2.64 (-7.08%)

AVP

Avon Products

$3.20

0.06 (1.91%)

MAXR

Maxar Technologies

$6.95

-0.525 (-7.03%)

JMIA

Jumia Technologies

$23.30

2.83 (13.83%)

BP

BP

$42.75

0.15 (0.35%)

BE

Bloom Energy

$12.27

0.58 (4.96%)

  • 22

    May

NVAX Novavax
$6.26

0.21 (3.47%)

03/19/19
SBSH
03/19/19
NO CHANGE
Target $1.25
SBSH
Buy
Citi cuts Novavax target to $1.25, sees three reasons to keep Buy
Citi analyst Joel Beatty lowered his price target for Novavax to $1.25 from $3.50 but maintains a Buy rating on the shares. While the recent failure of the Phase 3 respiratory syncytial virus vaccine trial was a "major setback" for the company, three potential upside opportunities collectively make the stock a Buy, Beatty tells investors in a research note. These include an accelerated approval pathway being confirmed by the FDA for NanoFlu, a scenario the analyst believes is "slightly more likely than not," a ResVax partnership is announced, and/or ResVax receiving approval in Europe.
03/19/19
HCWC
03/19/19
NO CHANGE
Target $2
HCWC
Buy
H.C. Wainwright sees pathway for Novavax approval, keeps $2 price target
Following the company's Q4 results and business update, H.C. Wainwright analyst Vernon Bernardino continues to believe a "strong investment thesis remains" for buying Novavax shares. The Prepare trial showed ResVax was safe, and importantly, resulted in clinically meaningful outcomes, Bernardino tells investors in a research note. While the stock remains down 76% from its closing price of $2.13 prior to the Prepare results, prospects for discussions with the FDA and European Medicines Agency, which are expected in the next 90 days, are positive, contends the analyst. He believe ResVax's pathway to approval is "under-appreciated" and would be a buyer of the stock. Bernardino keeps a Buy rating on Novavax with a $2.00 price target. The stock in midday trading is down fractionally at 52c.
05/13/19
OPCO
05/13/19
NO CHANGE
Target $25
OPCO
Outperform
Novavax price target raised to $25 from $1.25 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Novavax to $25 from $1.25 to reflect the company's 1-for-20 stock split, effective May 10. The analyst reiterates an Outperform rating on the shares.
05/06/19
SBSH
05/06/19
NO CHANGE
Target $0.95
SBSH
Buy
Citi recommends buying Novavax ahead of regulatory update
Citi analyst Joel Beatty recommends buying Novavax because he sees a "favorable likelihood" that a regulatory update in the next month or so will reveal that the company can pursue the accelerated approval pathway for its flu vaccine. This would allow for Phase 3 results around January 2020, Beatty tells investors in a research note. The analyst sees ~25% upside / ~50% downside on whether accelerated approval is granted. He lowered his price target for Novavax shares to 95c from 95c from $1.25 and keeps a Buy rating on the shares.
AKRX Akorn
$4.41

0.215 (5.13%)

05/08/19
RBCM
05/08/19
NO CHANGE
Target $5
RBCM
Sector Perform
Akorn price target raised to $5 from $4 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Akorn to $5 with a Sector Perform and Speculative Risk rating following the company's above consensus Q1 earnings and FY19 guidance. The analyst expects the outlook to reduce the uncertainty that had previously constrained the stock price, but also sees a "long way" toward getting past the company's manufacturing challenges and high leverage.
03/19/19
RHCO
03/19/19
INITIATION
Target $4
RHCO
Hold
Akorn initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert started Akorn with a Hold rating and $4 price target. The company is dealing with quality issues at key facilities that could delay new approvals and potentially impact on-market products, Gilbert tells investors in a research note. Further, he believes that while expectations have been reset, the stock is "not inexpensive relative to its peers."
03/11/19
JMPS
03/11/19
NO CHANGE
JMPS
Market Perform
Akorn is currently fairly valued, says JMP Securities
Akorn's Q4 results were negatively impacted by manufacturing issues, and the company is dedicating 2019 to remediating the issues, JMP Securities analyst Donald Ellis tells investors in a post-earnings research note. The company also experienced increasing competition for multiple products and lower overall prices impacting revenues, the analyst adds. Ellis believes Akorn's new management team is equipped to expedite its manufacturing remediation and re-start new drug submissions and approvals. However, he finds the stock currently fairly valued and maintains a Market Perform rating on the name.
12/10/18
PIPR
12/10/18
NO CHANGE
Target $9
PIPR
Overweight
Piper does not view Akorn as 'major fixer-upper,' keeps $9 target
Piper Jaffray analyst David Amsellem says he would not view Akorn (AKRX) as a "major fixer-upper" now that it is planning to move forward as a stand-alone company. Much of the pressure on EBITDA in recent years was a function of limited-competition products with brand-like margins, Amsellem tells investors in a research note. Further, the rest of Akorn's product portfolio appears to be stable, says the analyst. In addition, "high-quality" abbreviated new drug application approvals have been happening, "and that matters," argues Amsellem. He keeps an Overweight rating on Akorn with a $9 price target.
UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$34.65

-2.64 (-7.08%)

AVP Avon Products
$3.20

0.06 (1.91%)

03/25/19
DADA
03/25/19
NO CHANGE
Target $3.5
DADA
Buy
Avon Products buyout could be valued as high as $4.50/shr, says DA Davidson
DA Davidson analyst Linda Bolton Weiser kept her Buy rating and $3.50 price target on Avon Products after the latest speculation about its potential acquisition by Natura. The analyst believes that the takeout valuation could come at $3.80-$4.50 per share, but intends to assess the Brazil anti-trust rules while also noting Natura's already "leveraged balance sheet, with over $2B of debt and debt-to-EBITDA of 4.3-times".
05/10/19
SBSH
05/10/19
NO CHANGE
SBSH
Natura paying 50% premium for Avon 'not the base case,' says Citi
Citi analyst Tobias Stingelin noted that Spanish website Intereconomia.com reported, citing a source, that Santander's board has approved a loan of up to $2.1B for Natura, which he notes has already publicly announced that it is engaged in talks to buy Avon. An all cash transaction of $2.1B, or a 50% premium, is unlikely in his view and he does not believe that this is the base case, Stingelin tells investors. He believes that if a transaction were to take place for Avon it would be at a lower premium and noted that Intereconomia's source said a deal could still be for a combination of cash and stock. Stingelin has a Neutral rating on Natura shares. In afternoon trading, Avon shares are up nearly 10% to $3.18.
09/24/18
09/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Plains All American (PAA) and Plains GP Holdings (PAGP) were upgraded to Buy from Hold at Stifel. 2. Avon Products (AVP) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser citing the increased "sense of urgency" under the new CEO Jan Zijderveld displayed in his first analyst meeting, demonstrating his greater engagement in the company's operations, hiring of executives with sales experience, and "establishing a culture of accountability." 3. United Natural Foods (UNFI) upgraded to Sector Perform at RBC Capital with analyst William Kirk saying while core business challenges for the company remain and the risk of the Supervalu acquisition integration continues, its 6.4-times earnings valuation likely accounts for these issues. 4. KVH Industries (KVHI) upgraded to Buy from Neutral at Chardan with analyst James McIlree saying he expects "continued strong growth" from its Agile Plans that should result in improved margins and increased financial predictability. 5. RELX (RELX) upgraded to Overweight from Equal Weight at Barclays with analyst Nick Dempsey saying he views the current valuation as attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/18
DADA
09/24/18
UPGRADE
Target $3.5
DADA
Buy
Avon Products upgraded to Buy at DA Davidson on operational focus of new CEO
As reported earlier, DA Davidson analyst Linda Bolton Weiser upgraded Avon Products (AVP) to Buy from Hold and raised her price target to $3.50 from $1.75. The analyst cites the increased "sense of urgency" under the new CEO Jan Zijderveld displayed in his first analyst meeting, demonstrating his greater engagement in the company's operations, hiring of executives with sales experience, and "establishing a culture of accountability". Based on her increased confidence in Avon's management team, Weiser also raised her target enterprise value to expected FY20 EBITDA target multiple to 6.5-times from 4.5-times, which is still a discount to other direct sellers like Nu Skin (NUS) and Herablife (HLF) trading at 11- to 12-times
MAXR Maxar Technologies
$6.95

-0.525 (-7.03%)

03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/01/19
03/01/19
DOWNGRADE
Target $9

Hold
Maxar Technologies downgraded to Hold at TD Securities after disappointing Q4
As previously reported, TD Securities analyst Tim James downgraded Maxar Technologies to Hold from Speculative Buy and lowered his price target to $9 from $18.50 after its below-consensus Q4 results. The analyst says his previous constructive thesis attributing the company's weakness to the divestable GEO comsat business was incorrect as the company indicated it will continue to operate it at a loss. James added that the EBITDA of Maxar's Services and Imagery segment was also soft and recommends that investors await for evidence of improvement before considering buying shares again.
03/01/19
TDSI
03/01/19
DOWNGRADE
TDSI
Hold
Maxar Technologies downgraded to Hold from Speculative Buy at TD Securities
03/01/19
CIBC
03/01/19
DOWNGRADE
CIBC
Underperformer
Maxar Technologies downgraded to Underperformer from Neutral at CIBC
JMIA Jumia Technologies
$23.30

2.83 (13.83%)

05/14/19
BREN
05/14/19
UPGRADE
Target $45
BREN
Buy
Jumia Technologies upgraded to Buy from Hold at Berenberg
Berenberg analyst Sarah Simon upgraded Jumia Technologies to Buy from Hold with a $45 price target.
05/14/19
MSCO
05/14/19
NO CHANGE
Target $22
MSCO
Underweight
Jumia Technologies price target lowered to $22 from $27 at Morgan Stanley
Morgan Stanley analyst Brian Nowak lowered his price target on Jumia Technologies to $22 from $27, stating that the higher than expected fulfillment costs reported in Q1 are notable given his previously expressed view that fulfillment cost leverage will be key to reaching profitability. Following the Q1 report, Nowak increased his forward fulfillment estimates, leading him to estimate higher EBITDA losses and trim his target. He keeps an Underweight rating on Jumia shares, citing his preference for large cap stocks with more upside and less execution risk.
05/14/19
05/14/19
UPGRADE
Target $36

Outperform
Jumia Technologies upgraded to Outperform on growth, valuation at Raymond James
As previously reported, Raymond James upgraded Jumia Technologies to Outperform from Market Perform and established a $36 price target following the strong Q1 report. Analyst Aaron Kessler believes the recent share declines provides a buying opportunity and expects strong GMV growth and margin improvement to continue. The analyst views Jumia as a leading pan-African eCommerce marketplace, expects robust growth to continue, and sees significant potential core strength in payments and other services.
05/14/19
SBSH
05/14/19
NO CHANGE
Target $30
SBSH
Neutral
Jumia Technologies price target lowered to $30 from $41 at Citi
Citi analyst Andrew Howell lowered his price target for Jumia Technologies to $30 from $41 saying that while the company reported "strong" Q1 results, operating expenses came in higher than he expected. Further, on the results call, management did not formally address the allegations raised by Citron Research last week, Howell tells investors in a research note. However, the analyst believes Jumia's progress towards growth and profitability targets is far more important than these allegations. Nonetheless, Howell thinks it may take some time for investor confidence to be restored. As such, he would welcome a more public response from the company in addressing the allegations. The analyst keeps a Neutral rating on Jumia Technologies.
BP BP
$42.75

0.15 (0.35%)

02/26/19
RBCM
02/26/19
NO CHANGE
RBCM
RBC upgrades Total, downgrades Shell after reserves analysis
RBC Capital analyst Biraj Bokhataria believes integrated oil and gas companies "could generate more free cash flow over the next few years than at any point over the last decade," but said the market continues to value them at a historical discount due to skepticism around the sharp drop in capex. Growing confidence in the outlook for reserves could lead to greater credibility in organic free cash flow, said Bokhataria, who sees stable to improving reserve life trends at BP (BP), Chevron (CVX), Eni (E), and Galp (GLPEY). Royal Dutch Shell (RDS.A) and Repsol (REPYY) screen as the weakest in his analysis, noted Bokhataria who downgraded Royal Dutch Shell to Sector Perform from Outperform following the reserves analysis. The analyst also said that, at today's share price, he thinks Shell needs at least another $30B in buybacks in order to reduce its dividend burden to a sustainable level and that buyback need could limit its options to high-grade its portfolio. Bokhataria also upgraded Total (TOT) to Outperform, as he sees the company's reserve life "to trickle lower," but mainly due to its "particularly strong growth pipeline," which he added comes from the most diverse set of projects in the sector.
03/05/19
MSCO
03/05/19
NO CHANGE
MSCO
Morgan Stanley downgrades Energy sector to Equal Weight from Overweight
Morgan Stanley equity strategist Michael Wilson said the firm's strategy team expects further declines in earnings forecasts for the Energy sector and are moving to Equal Weight from Overweight on the sector while they remain overweight Utilities. The firm's Energy and Utilities analysts highlight Baker Hughes (BHGE), Bloom Energy (BE), BP (BP), ConocoPhillips (COP), FirstEnergy (FE), Marathon Petroleum (MPC), Suncor (SU), TechnipFMC (FTI) and Tenaris (TS) as their top picks.
04/16/19
RBCM
04/16/19
DOWNGRADE
Target $49.1
RBCM
Outperform
BP downgraded to Outperform from Top Pick at RBC Capital
RBC Capital analyst Biraj Borkhataria downgraded BP to Outperform from Top Pick and lowered his price target for the shares to $49.10 from $49.60. The analyst cites valuation for the downgrade following the recent rally in the shares. Borkhataria continues to be positive on the outlook for integrated oil majors but sees modest downside to Q1 estimates.
04/16/19
04/16/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HollyFrontier (HFC) downgraded to Sell from Neutral at Goldman Sachs with analyst Neil Mehta saying he now sees a less attractive crude differential environment given a narrower Brent-WTI and WTI-WCS spread forecast in 2019 and 2020. 2. BP (BP) downgraded to Outperform from Top Pick at RBC Capital with analyst Biraj Borkhataria citing valuation. 3. Cisco (CSCO) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Rod Hall saying Cisco has executed well on rolling out its Catalyst 9000 products that have driven "solid" double digit growth in campus switching revenues. 4. DowDuPont (DWDP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the impact of the company's spinoff of Dow on April 2nd. 5. EOG Resources (EOG) and EQT Corporation (EQT) downgraded to Neutral from Buy at MKM Partners. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BE Bloom Energy
$12.27

0.58 (4.96%)

02/13/19
02/13/19
UPGRADE
Target $13

Outperform
Bloom Energy upgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James analyst Pavel Molchanov upgraded Bloom Energy to Outperform from Market Perform, with a $13 price target. The analyst notes that shares are down about 36% since the IPO in July 2018, including a 24% drop since mid-January, the latter due in large part to selling pressure following lockup expiration. With the broad contours of the story little-changed over the past seven months, the stock's intense sentiment-driven volatility has created what the analyst views as an attractive entry point.
02/13/19
02/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Piyush Sood saying his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2, given falling global production, low visible inventories and improved demand from China and Freeport's earnings sensitivity to copper is still the highest among its peers. 2. DocuSign (DOCU) upgraded to Buy from Hold at Deutsche Bank with analyst Karl Keirstead saying that after speaking with four large e-signature customers, three using DocuSign and one using Adobe Sign, the analyst believes a "more constructive call on DocuSign shares is now warranted." 3. Bloom Energy (BE) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying shares are down about 36% since the IPO in July 2018, including a 24% drop since mid-January, the latter due in large part to selling pressure following lockup expiration. 4. Shopify (SHOP) upgraded to Outperform from Sector Perform at RBC Capital with analyst Ross MacMillan saying he anticipates the company to return to new merchant growth this year given its international opportunity and easier comps. 5. Myovant Sciences (MYOV) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying his firm's women's health survey suggests a "robust potential market" for new treatment options for endometriosis and uterine fibroids. The analyst also raised his price target for the shares to $25 from $22. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/12/19
JPMS
03/12/19
NO CHANGE
JPMS
JPMorgan likes four stocks in Alternative Energy
JPMorgan analyst Paul Coster says his Alternative Energy picks for 2019 remain Bloom Energy (BE), First Solar (FSLR), Hannon Armstrong (HASI), and TPI Composites (TPIC). The "decent" year-to-date gains notwithstanding, these four stocks offer favorable risk-reward opportunities through year-end, with Bloom and First Solar offering the highest return potential, Coster tells investors in a research note. He believes Alternative Energy fundamentals remain favorable across the spectrum of technologies, driven by "increasingly attractive unit-economics." This could be a "rare banner year for investors in Alt Energy SMid-Cap Stocks," says Coster.

TODAY'S FREE FLY STORIES

LGCY

Legacy Reserves

$0.11

-0.0195 (-15.12%)

21:00
06/18/19
06/18
21:00
06/18/19
21:00
Hot Stocks
Legacy Reserves files for Chapter 11 »

Legacy Reserves announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NANO

Nanometrics

$33.56

1.07 (3.29%)

20:33
06/18/19
06/18
20:33
06/18/19
20:33
Initiation
Nanometrics initiated at B. Riley FBR »

Nanometrics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

, SPX

S&P 500

$0.00

(0.00%)

20:26
06/18/19
06/18
20:26
06/18/19
20:26
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump asked lawyers about…

SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
06/18/19
06/18
20:25
06/18/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

AMZN

Amazon.com

$1,902.00

16.45 (0.87%)

, FDX

FedEx

$166.32

2.61 (1.59%)

20:02
06/18/19
06/18
20:02
06/18/19
20:02
Periodicals
Amazon.com expanding next-day delivery with more rented jets, WSJ says »

Amazon.com (AMZN) is…

AMZN

Amazon.com

$1,902.00

16.45 (0.87%)

FDX

FedEx

$166.32

2.61 (1.59%)

UPS

UPS

$102.16

0.76 (0.75%)

BA

Boeing

$374.21

19.31 (5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 09

    Jul

  • 10

    Jul

  • 24

    Jul

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

DLAKY

Lufthansa

$0.00

(0.00%)

19:53
06/18/19
06/18
19:53
06/18/19
19:53
Downgrade
Lufthansa rating change at Nord/LB »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEQU

Kewaunee Scientific

$22.34

0.44 (2.01%)

19:45
06/18/19
06/18
19:45
06/18/19
19:45
Earnings
Kewaunee Scientific reports Q4 EPS (15c) excluding cost items, one estimate 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.71

0.58 (1.61%)

19:08
06/18/19
06/18
19:08
06/18/19
19:08
Periodicals
GM, UAW negotiating to hire more temps, cut $900M in health cost, Bloomberg says »

General Motors is seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

FLXS

Flexsteel Industries

$16.77

-0.13 (-0.77%)

19:04
06/18/19
06/18
19:04
06/18/19
19:04
Hot Stocks
Flexsteel Industries updates on restructuring, to incur $48M-$53M charge »

Flexsteel Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

, JBL

Jabil

$27.33

0.53 (1.98%)

19:02
06/18/19
06/18
19:02
06/18/19
19:02
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Adobe…

ADBE

Adobe

$276.80

1.21 (0.44%)

JBL

Jabil

$27.33

0.53 (1.98%)

X

U.S. Steel

$14.58

0.62 (4.44%)

ARQL

ArQule

$9.37

-0.19 (-1.99%)

UPWK

Upwork

$15.15

-0.29 (-1.88%)

MTSI

Macom

$14.40

-0.02 (-0.14%)

LZB

La-Z-Boy

$29.76

-0.47 (-1.55%)

KURA

Kura Oncology

$18.73

-0.76 (-3.90%)

GPRE

Green Plains

$12.48

0.3 (2.46%)

NCR

NCR Corp.

$31.34

0.31 (1.00%)

ZYME

Zymeworks

$20.15

-0.51 (-2.47%)

GNCA

Genocea

$5.16

-0.24 (-4.44%)

YY

YY

$77.13

2.14 (2.85%)

EAF

GrafTech

$10.95

0.14 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 25

    Jun

  • 20

    Jun

PCG

PG&E

$19.15

0.27 (1.43%)

18:59
06/18/19
06/18
18:59
06/18/19
18:59
Periodicals
PG&E to pay $1B to some CA communities to settle wildfire claims, WSJ says »

PG&E has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

STOK

Stoke Therapeutics

$0.00

(0.00%)

18:46
06/18/19
06/18
18:46
06/18/19
18:46
Syndicate
Stoke Therapeutics 7.89M share IPO priced at $18.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

LTXB

LegacyTexas Financial

$39.02

0.11 (0.28%)

18:36
06/18/19
06/18
18:36
06/18/19
18:36
Downgrade
LegacyTexas Financial rating change at SunTrust »

LegacyTexas Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

UNP

Union Pacific

$165.49

0.885 (0.54%)

18:24
06/18/19
06/18
18:24
06/18/19
18:24
Hot Stocks
Union Pacific CEO: The President is addressing the right topics with China »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

MYOS

MYOS

$1.40

0.11 (8.53%)

18:12
06/18/19
06/18
18:12
06/18/19
18:12
Hot Stocks
MYOS says fortetropin shows increase rate of muscle protein synthesis in study »

MYOS RENS Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.71

0.58 (1.61%)

18:06
06/18/19
06/18
18:06
06/18/19
18:06
Periodicals
Breaking Periodicals news story on General Motors »

GM, UAW negotiating to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

BXC

BlueLinx

$22.03

0.305 (1.40%)

18:00
06/18/19
06/18
18:00
06/18/19
18:00
Hot Stocks
BlueLinx sells two distribution facilities for $12M »

BlueLinx Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

, BA

Boeing

$374.21

19.31 (5.44%)

17:59
06/18/19
06/18
17:59
06/18/19
17:59
Periodicals
U.S. expected to be open to ending aircraft subsidy dispute, Reuters says »

The U.S. is expected to…

EADSY

Airbus

$0.00

(0.00%)

BA

Boeing

$374.21

19.31 (5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

FB

Facebook

$188.46

-0.43 (-0.23%)

17:56
06/18/19
06/18
17:56
06/18/19
17:56
Periodicals
House Banking chair Waters calls on Facebook to halt Libra, Reuters says »

House Financial Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

OII

Oceaneering

$18.34

0.7 (3.97%)

, APC

Anadarko

$69.95

0.16 (0.23%)

17:36
06/18/19
06/18
17:36
06/18/19
17:36
Hot Stocks
Oceaneering awarded supply contract for Mozambique LNG Project »

Oceaneering (OII)…

OII

Oceaneering

$18.34

0.7 (3.97%)

APC

Anadarko

$69.95

0.16 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

GVA

Granite Construction

$44.64

1.335 (3.08%)

17:35
06/18/19
06/18
17:35
06/18/19
17:35
Hot Stocks
Granite Construction JV awarded $275M highway construction project in Sacremento »

Granite Construction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$69.95

0.16 (0.23%)

, FTI

TechnipFMC

$23.76

0.7 (3.04%)

17:33
06/18/19
06/18
17:33
06/18/19
17:33
Hot Stocks
TechnipFMC awarded subsea contracts by subsidiary of Anadarko Petroleum »

TechnipFMC (FTI) has been…

APC

Anadarko

$69.95

0.16 (0.23%)

FTI

TechnipFMC

$23.76

0.7 (3.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 25

    Jul

MDT

Medtronic

$97.96

0.65 (0.67%)

17:33
06/18/19
06/18
17:33
06/18/19
17:33
Hot Stocks
Medtronic exec Surface sells 9,000 ordinary shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

EAF

GrafTech

$10.95

0.14 (1.30%)

17:20
06/18/19
06/18
17:20
06/18/19
17:20
Syndicate
Breaking Syndicate news story on GrafTech »

GrafTech files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$69.95

0.16 (0.23%)

17:12
06/18/19
06/18
17:12
06/18/19
17:12
Hot Stocks
Anadarko Area 1 Plan of Development now effective »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.